2. Cell Cycle/DNA Damage Apoptosis
  3. DNA Alkylator/Crosslinker Apoptosis
  4. Bendamustine

Bendamustine  (Synonyms: SDX-105 free base)

Cat. No.: HY-13567 Purity: 99.54%
SDS COA Handling Instructions

Molarity Calculator

Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties.

For research use only. We do not sell to patients.

Bendamustine Chemical Structure

Bendamustine Chemical Structure

CAS No. : 16506-27-7

Size Price Stock Quantity
1 mg USD 42 In-stock
5 mg USD 90 In-stock
10 mg USD 150 In-stock
25 mg USD 330 In-stock
50 mg USD 520 In-stock
100 mg USD 830 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Bendamustine:

Bendamustine Related Antibodies

Top Publications Citing Use of Products

    Bendamustine purchased from MedChemExpress. Usage Cited in: J Biomed Res. 2017 0(0): 1-12.

    Testis cross-sections are stained with anti-PLZF antibody (red), and Hoechst 33342 (blue). Higher magnification images showing localization of PLZF-positive spermatogonia stem cells at the base of the seminiferous epithelium in contact with the basal membrane (arrows indicate PLZF+cells). A, B: sections from the testis of Bendamustine (BD) control mice and BD treated mice.

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties[1].

    IC50 & Target

    DNA Alkylator/Crosslinker[1]
    Cellular Effect
    Cell Line Type Value Description References
    A549 IC50
    > 92.93 μM
    Compound: Bendamustine
    Cytotoxicity against Homo sapiens (human) A549 cells after 24 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) A549 cells after 24 hr by MTT assay
    		10.1007/s00044-011-9959-8
    HCT-116 IC50
    71.69 μM
    Compound: Bendamustine
    Cytotoxicity against Homo sapiens (human) HCT116 cells after 24 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HCT116 cells after 24 hr by MTT assay
    		10.1007/s00044-011-9959-8
    HeLa IC50
    > 20 μM
    Compound: Bendamustine
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 35477142]
    HeLa IC50
    > 20 μM
    Compound: Bendamustine
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method
    		[PMID: 33261898]
    HL-60 IC50
    6.98 μM
    Compound: Bendamustine
    Cytotoxicity against Homo sapiens (human) HL60 cells after 24 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HL60 cells after 24 hr by MTT assay
    		10.1007/s00044-011-9959-8
    KB IC50
    41.28 μM
    Compound: Bendamustine
    Cytotoxicity against Homo sapiens (human) KB cells after 24 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) KB cells after 24 hr by MTT assay
    		10.1007/s00044-011-9959-8
    MDA-MB-231 IC50
    13.28 μM
    Compound: Bendamustine
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 35477142]
    MDA-MB-231 IC50
    13.28 μM
    Compound: Bendamustine
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method
    		[PMID: 33261898]
    Panel NCI-60 cells GI50
    70 μM
    Compound: 55
    Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay
    Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay
    		[PMID: 29870668]
    In Vitro

    Bendamustine is a DNA cross-linking agent that causes DNA breaks, with alkylating and antimetabolite properties. Bendamustine uniquely regulates apoptosis pathways and DNA repair pathways in non-Hodgkin's lymphoma cells. Bendamustine (50 μM) induces p21 (Cip1/Waf1) and NOXA genes, and increases the expression of p53 in SU-DHL-1 cells. Bendamustine (25 μM) blocks mitotic checkpoints and cuases mitotic catastrophe[1].
    Bendamustine reduces the viability of multiple myeloma (MM) cell lines, such as RPMI-8226 and 8226-LR5 cells, with IC25s of 101.8 μM and 585.5 μM after 24 h incubation, and 51.7 and 374.3 μM after 48 h incubation, respectively. Bendamustine induces a specific caspase-dependent MM cell death and inhibits the spindle-assembly checkpoint[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Bendamustine Related Antibodies
    In Vivo

    Bendamustine (25 mg/kg, i.v.) shows potent inhibition on the growth of tumor cells by 91%, 99% and 95% for DoHH-2, Granta 519 and RAMOS models, respectively. Moreover, the antitumor effect of Bendamustine is enhanced by rituximab in DoHH-2 and RAMOS models, but not in Granta 519 model[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    358.26

    Formula

    C16H21Cl2N3O2
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    -20°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (279.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.7913 mL 13.9563 mL 27.9127 mL
    5 mM 0.5583 mL 2.7913 mL 5.5825 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (6.98 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (6.98 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References
    Cell Assay
    [2]

    Cytotoxicity of both Bendamustine and melphalan on multiple myeloma (MM) cells is calculated as inhibition of cell viability by measuring the percentage of cell survival by MTS assay. Briefly, cells (1 × 104/well) are seeded in 96-well plates with increasing concentrations of the drug and analyzed after 24, 48, 72 and 96 h of incubation. To this end, 1 μg/mL of MTS solution is added to each well and, after 1 h at 37 °C, the dark blue formazan crystals are dissolved by isopropanol 1 N and HCl (24:1, vol/vol). Finally, the absorbance is measured at 490 nm in a 96-well plate reader. Cell survival is estimated as the percentage of the absorbance of untreated controls and each test is performed in triplicate. The inhibitory concentrations 50 (IC50) and 25 (IC25) of each drug, being the amount able to reduce cell growth to 50% and 25%, respectively, of that of untreated control cells, are calculated, and the tests are performed in parallel using equitoxic concentrations of Bendamustine and melphalan. The relative resistance index (RRI) is expressed as the ratio of the IC50 of 8226-LR5 to the IC50 of RPMI-8226 cells[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [3]

    Mice[3]
    C.B.-17 scid mice (DoHH-2, Granta 519) or C.B.-17 scid-bg mice (SuDHL-4, RAMOS) are inoculated with 1 × 106 (DoHH-2, RAMOS), 3 × 106 (SuDHL-4) or 5 × 106 (Granta 519) cells s.c. in the right flank. For flank xenografts, inoculation volume is 0.2 mL consisting of a 50:50 mixture of cells in growth medium and Matrigel. Tumour volume is estimated by two to three weekly measurements of the length and width of the tumour by electronic calipers and applying the following equation: V=L×W2/2. Tumours are allowed to reach approximately 250 mm3, and mice are size-matched (day 0) into treatment and control groups. For systemic Granta 519 tumour models, 2 × 106 cells are injected via the tail vein in 0.1 mL volume of cell medium on day 0, and treatment is initiated on day 14. All animals are ear-tagged and monitored individually throughout the experiment. Navitoclax is administered by oral gavage once daily in a mixture of Phosal 50PG : PEG400 : ethanol. Bendamustine and rituximab are administered i.v. at 25 mg/kg and 10 mg/kg, respectively, on day 1. Navitoclax is administered approximately 2 h before Bendamustine and rituximab. All trials are comprised of 10 mice per group. Mice are humanely killed when tumours reach a size >2000 mm3 or when any signs of distress are monitored. Signs of distress include loss of ambulation, laboured breathing or weight loss > 20% mean body weight per cage[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.7913 mL 13.9563 mL 27.9127 mL 69.7817 mL
    5 mM 0.5583 mL 2.7913 mL 5.5825 mL 13.9563 mL
    10 mM 0.2791 mL 1.3956 mL 2.7913 mL 6.9782 mL
    15 mM 0.1861 mL 0.9304 mL 1.8608 mL 4.6521 mL
    20 mM 0.1396 mL 0.6978 mL 1.3956 mL 3.4891 mL
    25 mM 0.1117 mL 0.5583 mL 1.1165 mL 2.7913 mL
    30 mM 0.0930 mL 0.4652 mL 0.9304 mL 2.3261 mL
    40 mM 0.0698 mL 0.3489 mL 0.6978 mL 1.7445 mL
    50 mM 0.0558 mL 0.2791 mL 0.5583 mL 1.3956 mL
    60 mM 0.0465 mL 0.2326 mL 0.4652 mL 1.1630 mL
    80 mM 0.0349 mL 0.1745 mL 0.3489 mL 0.8723 mL
    100 mM 0.0279 mL 0.1396 mL 0.2791 mL 0.6978 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Bendamustine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Bendamustine16506-27-7SDX-105SDX105SDX 105DNA Alkylator/CrosslinkerApoptosisDNApurinealkylatinganticancerantimetaboliteInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Bendamustine
    Cat. No.:
    HY-13567
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (644 KB) Français - FR (644 KB) Deutsch - DE (644 KB) Norwegian - NO (644 KB) Español - ES (644 KB) Swedish - SV (644 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.